Corporation
GlaxoSmithKline Inc.
- Meetings this Parliament
- 48
- With MPs
- 11
- Since Nov 2021
- 166
- Active registrations
- 1
Most recent reported meeting: Sep 15, 2026.
Lobbying by GlaxoSmithKline Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Sep 15, 2026
Filed by Tina Graves, President and General Manager, GSK Canada
Lobbyists
- Alain Couture · External Affairs Manager
- Alison Pozzobon · Vice President Communications, Government Affairs and Market Access
- Bryan Tennant · Scientific Director
- Emily Beduz · Manager, Federal Affairs
- Gilda Volpentesta · VP of Regulatory
- Ian Robertson · Senior Manager, Government Affairs and Public Health
- Kevin Sauve · National Public Health Manager
- Lisa Lovlin · Senior Manager, Government Affairs and Public Health
- Luke Miels · Global CEO
- Michelle Horn · VP & Country Medical Director
- Ryan Lock · Manager, National Policy - Federal Affairs
- Shawn White · External Affairs Manager
- Stephen Burke · National Policy Manager - Oncology
- Steven A Roberts · Director, Scientific Collaborations
- Tina Graves · President and General Manager, GSK Canada
Institutions they may lobby: Canadian Heritage (PCH), Correctional Service of Canada (CSC), Employment and Social Development Canada (ESDC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Immigration, Refugees and Citizenship Canada (IRCC), Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Justice Canada (JC), Pacific Economic Development Canada (PacifiCan), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)
What they're lobbying on (26)Hide details
- Engagement with the Government regarding the Life Science Fund seeking partnership and funding to support completion of Phase I and Phase II clinical research program associated to AMR (antimicrobial resistance)
- Antimicrobial Resistance (AMR) - Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR. Also discuss any applicable conditions regarding this funding.
- Programs and policy to support Canadian biomanufacturing and access to medicines and vaccines for Canadians.
- National Immunization Strategy and policies and programs that impact public access to vaccines and disease prevention in Canada.
- Patented Medicines Review Board (PMPRB), certified under the Patent Act and whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development.
- Engagement with federal officials regarding the Biomanufacturing & Life Sciences Strategy and policies and programming related to biomanufacturing in Canada
- Access to medicines - government policies, processes, legislation, and/or regulation with potential impact on access to medicines in Canada.
- Trade-related matters, including policies and tariffs impacting medicines and vaccines.
- Policies and programs related to the health of new immigrants to Canada.
- Policies, programs, and funding related to Canada's Sexually Transmitted and Blood-Borne Infections (STBBI) Action Plan 2024-2030.
- Engagement with federal officials regarding Health Emergency Readiness Canada.
- The National Pharmaceutical Strategy (NPS) as agreed by First Ministers in 2004. Advocacy for ways to increase access to medicines and vaccines for Canadian patients.
- The Common Drug Review (CDR) process for reviewing new drugs and providing listing recommendations to publicly funded drug benefit plans in Canada. Ensuring the access needs of Canadian patients are met by advocating on activities undertaken in the context of the CDR.
- Science and Technology (S&T) Strategy: Mobilizing Science and Technology to Canada's Advantage. Advocacy for measures which will allow for commercialization in health care to occur and for Canada to remain competitive internationally on Intellectual Property and other fronts.
- Public Services and Procurement Canada (PSPC) Integrity Framework - Clarifying the process for procurement of vaccines and possibly pharmaceuticals under the evolving procurement framework.
- Patented Medicines (Notice of Compliance) Regulations which seek to balance the protection of Intellectual Property (IP) and patents with cost containment. Advocacy to ensure that IP rights are respected and internationally competitive in order to promote Research and Development.
- Legislation, regulations, policies and programs concerning the federal government's response to COVID-19, including pandemic preparedness, pharmaceutical and vaccine supply-chain management, and general administration of justice.
- Food and Drugs Act and the bill formerly known as Bill C-51: An Act to amend the Food and Drugs Act and to make consequential amendments to other Acts. Specifically, with respect to the renewal of the drug approval process. Advocacy to ensure that Canada's review and approval process is timely, safe, effective, competitive and consistent with other jurisdictions.
- FedDev Ontario Advanced Manufacturing Fund - advancing manufacturing of innovative pharmaceutical products in southern Ontario
- Engage with government to strengthen the Priority Review for Drug Submissions process.
- Engage the Government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians.
- Engagement with the Government regarding the Strategic Innovation Fund
- Drug Re-importation - Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level re-importation legislation.
- Canada’s Access to Medicines Regime (CAMR), certified under the Patent Act, which allows developing countries to access drugs at a lower cost, with regard to ensuring that Intellectual Property rights and anti-diversion mechanisms continue to be respected.
- Canada-Europe Comprehensive Economic and Trade Agreement - Intellectual Property Provisions
- Canada-European Union Comprehensive Economic Trade Agreement with respect to strengthening Intellectual Property Protection provisions under the Patent Act and related regulations.
Registration 966444-5088-90. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Sridhar Venkatesh (145), Zach Gana (10), Faris El-Refaie (8), Tina Graves (3).
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Jocelyn Milburn · Director, Innovation, Science and Economic Development Canada (ISED)
Engagement with federal officials regarding the Biomanufacturing & Life Sciences Strategy Read more
Access to medicines - government policies, processes, legislation, and/or regulation with potential impact on access to medicines in Canada.
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Jacqueline Arthur · Director, AMR Pilot, Public Health Agency of Canada (PHAC)
- Kanchana Amaratunga · Public Health Medical Advisor, Public Health Agency of Canada (PHAC)
Antimicrobial Resistance (AMR) - Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR. Read more
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
Trade-related matters, including policies and tariffs impacting medicines and vaccines. Read more
Antimicrobial Resistance (AMR) - Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR.
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Stephen Ellis · Member of Parliament, House of Commons
Engagement with federal officials regarding the Biomanufacturing & Life Sciences Strategy Read more
Access to medicines - government policies, processes, legislation, and/or regulation with potential impact on access to medicines in Canada.
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Melissa Sutherland · Director General, Health Canada (HC)
Engagement with federal officials regarding the Biomanufacturing & Life Sciences Strategy Read more
Engagement with federal officials regarding Health Emergency Readiness Canada.
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Erin Henry · Director General, Public Health Agency of Canada (PHAC)
- Matthew Tunis · Executive Secretary, Public Health Agency of Canada (PHAC)
- Heather Deehan · Director, Public Health Agency of Canada (PHAC)
- Michael Pignat · Manager, Procurement, Public Health Agency of Canada (PHAC)
Trade-related matters, including policies and tariffs impacting medicines and vaccines. Read more
National Immunization Strategy. Advocacy to seek continued investment in vaccines funding and an overall strategy for prevention of disease in Canada.
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
- Jocelyn Milburn · Director, Innovation, Science and Economic Development Canada (ISED)
Trade-related matters, including policies and tariffs impacting medicines and vaccines. Read more
Engagement with federal officials regarding Health Emergency Readiness Canada.
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Eric Nicol · Director of Policy, Employment and Social Development Canada (ESDC)
National Immunization Strategy. Advocacy to seek continued investment in vaccines funding and an overall strategy for prevention of disease in Canada.
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Antimicrobial Resistance (AMR) - Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR. Read more
Engagement with federal officials regarding Health Emergency Readiness Canada.
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Kasondra White · Director, Innovation, Science and Economic Development Canada (ISED)
Engagement with federal officials regarding the Biomanufacturing & Life Sciences Strategy Read more
Engagement with federal officials regarding Health Emergency Readiness Canada.
-
Reported by Sridhar Venkatesh · In-house (corporation)
- François-Philippe Champagne · Minister, Innovation, Science and Economic Development Canada (ISED)
- Laurel Chester · Sr Advisor, Innovation, Science and Economic Development Canada (ISED)
- Philip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Engagement with federal officials regarding the Biomanufacturing & Life Sciences Strategy Read more
Engagement with the Government regarding the Strategic Innovation Fund
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Erin Henry · Director General, Public Health Agency of Canada (PHAC)
- Jacqueline Kosche · Director, Vaccine Logistics and Operations, Public Health Agency of Canada (PHAC)
- Natalie Gravelle · A/ Director, Public Health Agency of Canada (PHAC)
National Immunization Strategy. Advocacy to seek continued investment in vaccines funding and an overall strategy for prevention of disease in Canada.
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Mohamed-Iqbal Ravalia · Senator, Senate of Canada
National Immunization Strategy. Advocacy to seek continued investment in vaccines funding and an overall strategy for prevention of disease in Canada. Read more
Antimicrobial Resistance (AMR) - Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR.
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Greg Orencsak · Deputy Minister, Health Canada (HC)
- Jill Norman · Director, Health Canada (HC)
- Amanda Ratz · Senior Advisor, Health Canada (HC)
Antimicrobial Resistance (AMR) - Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR. Read more
Policies, programs, and funding related to Canada's Sexually Transmitted and Blood-Borne Infections (STBBI) Action Plan 2024-2030.
National Immunization Strategy. Advocacy to seek continued investment in vaccines funding and an overall strategy for prevention of disease in Canada.
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Mark Holland · Minister of Health, Health Canada (HC)
- Eshan Naik · Director of Policy, Health Canada (HC)
Antimicrobial Resistance (AMR) - Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR. Read more
National Immunization Strategy. Advocacy to seek continued investment in vaccines funding and an overall strategy for prevention of disease in Canada.
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Jean-Yves Duclos · Member of Parliament
- Loic Pare · Regional Affairs Advisor, Public Services and Procurement Canada (PSPC)
Public Services and Procurement Canada (PSPC) Integrity Framework - Clarifying the process for procurement of vaccines and possibly pharmaceuticals under the evolving procurement framework. Read more
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Heather Earle · Manager, Innovation, Science and Economic Development Canada (ISED)
- Bryan Dalphy · Deputy Director, Innovation, Science and Economic Development Canada (ISED)
- Kasondra White · Director, Innovation, Science and Economic Development Canada (ISED)
and 1 moreShow fewer
- Simon Young · Senior Policy Analyst, Innovation, Science and Economic Development Canada (ISED)
Engagement with federal officials regarding Health Emergency Readiness Canada.
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Jacqueline Arthur · Director, innovative Supply Solutions: AMR, CVTR, Public Health Agency of Canada (PHAC)
- Niyi Lawuyi · Manager of Supply Access and Logistics, Public Health Agency of Canada (PHAC)
- Christina Surujballi · Senior Policy Analyst, Public Health Agency of Canada (PHAC)
- Bronwen Clark-Brewin · Policy Analyst, Public Health Agency of Canada (PHAC)
and 4 moreShow fewer
- Joshua Atkinson · Project Manager, Public Health Agency of Canada (PHAC)
- Dylan Kovacs · Policy analyst, Public Health Agency of Canada (PHAC)
- Nesreen Mandanas · Policy Analyst, Public Health Agency of Canada (PHAC)
- Kathleen Dunn · Senior advisor, Public Health Agency of Canada (PHAC)
Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR. Read more
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Greg Orencsak · Deputy Minister, Health Canada (HC)
- Michelle Boudreau · Executive Director, Health Canada (HC)
- Melissa Sutherland · A/ Director General, Health Canada (HC)
Engagement with federal officials regarding the Biomanufacturing & Life Sciences Strategy Read more
Engagement with federal officials regarding Health Emergency Readiness Canada.
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
Engagement with federal officials regarding Health Emergency Readiness Canada.
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Kasondra White · Director, Innovation, Science and Economic Development Canada (ISED)
- Bryan Dalphy · Deputy Director, Innovation, Science and Economic Development Canada (ISED)
Economic DevelopmentHealth
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Shuvaloy Majumdar · Member of Parliament
Economic DevelopmentHealth
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Mohamed-Iqbal Ravalia · Senator, Senate of Canada
Health
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Yasir Naqvi · Member of Parliament
Health
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Joel Denis · Director General, Public Health Agency of Canada (PHAC)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
- Greg Orencsak · Deputy Minister, Health Canada (HC)
- Eric Costen · Associate Deputy Minister, Health Canada (HC)
Economic DevelopmentHealthResearch and Development
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.